OUR IMPACT
Collaborative success
Etcembly has demonstrated EMLy’s real-world impact through multiple industry partnerships.
-
With Twist Bioscience: Codon-optimization models achieved >96% success.
-
With Vector Labs: EMLy resolved major developability challenges for an antibody candidate, improving expression, yield, and aggregation profiles in over 80% of engineered variants.
-
Etcembly’s internal pipeline: The platform enabled a high-affinity T-cell engager in just six months.
-
Through Patsnap integration: Users gain seamless access to curated patent data, sequence intelligence, and competitive insights.
Note from DAVE:
I suggest that a partner page could be beneficial. The current placeholder copy has been written by me. If you agree that this page would be useful then we'll need to brief Leida to write-up properly.
THE OPPORTUNITY
Turn scientific ambition into meaningful results
Note from DAVE:
These figures are taken from a competitor website. We should research our own data.
12-15y
With the current pharmaceutical R&D
model, it takes about 12 to
15 years to bring a new drug to market.
$2.5B
The estimated cost of research and development sits at over $2.5 billion per drug approval, increasing at a rate of 8.5% each year.
10%
More than 90% of drug candidates that enter Phase 1 clinical trials fail to reach regulatory approval, often due to the limited predictive value of preclinical models of disease.
70
Drug approvals remain stagnant in the current model. Fewer than 100 new drugs enter the market each year. With such a low yield, scalability is nearly impossible.
